December 11, 2013 09:00 ET

BIOLASE Adds Two New Independent Directors to Its Board

Finance and Accounting Executive James R. Talevich and Professor Samuel B. Low of University of Florida's Department of Periodontology Join Board of Directors

IRVINE, CA--(Marketwired - Dec 11, 2013) - BIOLASE, Inc. (NASDAQ: BIOL), the world's leading manufacturer and distributor of dental lasers, and a pioneer in laser surgery in other medical specialties, today announced that the Board of Directors (the "Board") has appointed James R. Talevich and Samuel B. Low, D.D.S., to the Board. Mr. Talevich and Dr. Low were appointed to the Audit Committee and Mr. Talevich was appointed Chairman of the Audit Committee. Gregory Lichtwardt and Erin Enright tendered their resignations from the Board on December 4, 2013. As a result of these appointments and resignations, BIOLASE's Board currently consists of six directors, four of whom are independent directors.

James R. Talevich has more than 23 years of experience as a senior financial executive, and is currently a director of Nova LifeStyle, Inc. (PINKSHEETS: STVS), an international manufacturing company, where he Chairs the Audit Committee and also serves on the Compensation and Nominating and Corporate Governance Committees. Mr. Talevich currently serves as a member of the Executive Committee and Advisory Council of the SEC Financial Reporting Institute at the USC Marshall School of Business, and as a member of the UCLA Anderson School of Management Alumni Board of Directors. He is also a member of the Concordia University Healthcare Management Advisory Board.

Mr. Talevich said, "BIOLASE has in place all of the elements necessary for great market success and a significant increase in shareholder value. BIOLASE has innovative products, patented technologies with widespread applicability, and large potential markets, as well as a talented management team and I look forward to the opportunity to contribute to its future success."
Prior to his current roles, Mr. Talevich served as Chief Financial Officer of I-Flow Corporation, a NASDAQ-listed medical technology company, from 2000 to 2009, Chief Financial Officer of Tectrix Fitness Equipment Inc. from 2005 to 2009, and Chief Financial Officer of Gish Biomedical, Inc., a NASDAQ-listed manufacturing company, from 1999 to 2000. From 2008 to 2009, he served on the Board of Directors of AcryMed, Inc., a developer of antimicrobial nanoparticle technologies. Mr. Talevich previously held financial and accounting positions with Mallinckrodt Group Inc., Sorin Biomedical (Fiat S.p.A.), Pfizer Inc., SensorMedics Corporation, Baxter International Inc., and KPMG. 

Mr. Talevich received a B.A. in physics from California State University, Fullerton, and an MBA from the UCLA Anderson School of Management. He is licensed as a Certified Public Accountant and is a member of the Forum for Corporate Directors, Financial Executives International, OCTANe, DeviceAlliance, and the California Society of CPAs.

"Jim Talevich brings to BIOLASE a powerful skill set that will serve our shareholders well in the coming years" said Federico Pignatelli, Chairman and Chief Executive Officer. "BIOLASE is poised to expand its business far beyond its current core base in dentistry, and that will require the depth of knowledge and breadth of experience in finance, compliance, governance and restructuring that he possesses."

Samuel B. Low, D.D.S. is Professor Emeritus of the Department of Periodontology at the University of Florida's College of Dentistry, where he has spent his entire academic career. Previously he served as Associate Dean for Continuing Education and Partnerships and Associate Dean for Administrative Affairs. Dr. Low also maintains an intramural practice, which includes periodontal dentistry and implants.

Dr. Low said, "I look forward to assisting BIOLASE in achieving its goals. Technology is the core value for the present and future of health care, and BIOLASE is in the unique visionary position to be at the forefront as the total dental technology provider. BIOLASE's revolutionary lasers are the central focus in managing my patients and I have been a proud user of WaterLase laser systems in my practice for the past nine years. WaterLase technology is truly a game-changer in surgery and the most versatile solution in providing quality dental care."

Dr. Low has served on the American Dental Association's Board of Trustees, as President of the Florida Dental Association and as a member of the American Academy of Periodontology. He has been on the editorial board of two academic journals related to dentistry.

Dr. Low received a B.S. from Lamar University and a D.D.S. from the University of Texas.

"Dr. Low is a very accomplished dental professional who has shaped the professional careers of literally thousands of dentists. He is a welcome addition to our Board, and we anticipate relying on his depth of expertise and knowledge to accelerate our growth in our core dental business in the coming years. We expect both Jim and Sam to be at the heart of the promising future that lies ahead for BIOLASE," concluded Pignatelli.

About BIOLASE, Inc.
BIOLASE, Inc. is a biomedical company that develops, manufactures, and markets innovative lasers in dentistry and medicine and also markets and distributes high-end 2D and 3D digital imaging equipment and CAD/CAM intraoral scanners and in-office milling machines; products that are focused on technologies that advance the practice of dentistry and medicine. The Company's proprietary laser products incorporate approximately 300 patented and patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. Its innovative products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold more than 24,000 lasers. Other laser products under development address ophthalmology and other medical and consumer markets.

For updates and information on WaterLase and laser dentistry, find BIOLASE online at, Facebook at, Twitter at, Pinterest at, LinkedIn at, Google+ at, Instagram at and YouTube at

BIOLASE® and WaterLase® are registered trademarks of BIOLASE, Inc.

Contact Information

  • For further information, please contact:
    Michael Porter
    Porter, LeVay & Rose, Inc.